secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2026-05-01T23:59:59+00:00
Accession:  0001437749-26-014315
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharmaceuticals launches HEMANGEOL Oral Solution for infantile hemangioma
------------------------------------------------------------------------------

- HEMANGEOL is the only FDA-approved treatment for proliferating infantile hemangioma requiring systemic therapy.
- Exclusively distributed through Anovo Specialty Pharmacy to streamline patient access and therapy initiation.
- Eton Cares support includes $0 co-pay for eligible commercially insured patients and expanded assistance programs.
- Estimated 5,000-10,000 infants treated annually in the U.S. with HEMANGEOL.
- Treatment window is typically 5 weeks to 5 months of age, lasting about 6 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926014315/0001437749-26-014315-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926014315/eton20260429_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-014315

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer